Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs

PHASE3CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

June 5, 2014

Primary Completion Date

July 12, 2016

Study Completion Date

July 12, 2016

Conditions
MyelomaVenous Thromboembolism
Interventions
DRUG

Apixaban

2.5mg x 2 per day during 6 months

Trial Locations (19)

24000

Ch de Perigueux, Périgueux

33604

Chu Bordeaux, Pessac

37000

Chru de Tours, Tours

38043

Chu Grenoble, Grenoble

59020

Hopital St Vincent - Ghicl, Lille

59037

Chru Hopital Huriez, Lille

59385

Centre Hospitalier, Dunkirk

64100

Ch La Cote Basque, Bayonne

69310

Ch Lyon Sud, Pierre-Bénite

69373

Centre Leon Berard, Lyon

72000

Clinique Victor Hugo, Le Mans

74374

CHRA, Annecy

75651

Hopital Pitie Salpetriere, Paris

76290

Groupe Hospitalier Du Havre, Montivilliers

85925

Chd Vendee, La Roche-sur-Yon

86021

Chu Poitiers, Poitiers

92141

Hia Percy, Clamart

94010

Chu Hopital Henri Mondor, Créteil

06202

Hopital de L'Archet, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

University Hospital, Grenoble

OTHER